23 patents
Utility
Engineered meganucleases that target human mitochondrial genomes
9 Jan 24
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA).
James Jefferson Smith, Ginger Tomberlin, John Morris, Wendy Shoop, Carlos T. Moraes
Filed: 30 Jan 23
Utility
Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
17 Oct 23
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene.
James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
Filed: 11 Apr 19
Utility
Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
17 Oct 23
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome.
James Jefferson Smith, Janel Lape, Victor Bartsevich, Hui Li
Filed: 20 Sep 21
Utility
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
12 Sep 23
The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene.
Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
Filed: 13 Sep 22
Utility
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
27 Sep 22
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
Filed: 14 Mar 22
Utility
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
12 Jul 22
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton
Filed: 26 Oct 21
Utility
Co-stimulatory domains for use in genetically-modified cells
29 Mar 22
The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition.
Derek Jantz, Aaron Martin, Jeffrey Sunman, Daniel T. MacLeod
Filed: 4 Oct 17
Utility
Engineered nucleases useful for treatment of hemophilia A
22 Mar 22
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene.
Derek Jantz, James Jefferson Smith, Victor Bartsevich, Clayton Beard, Michael G. Nicholson
Filed: 3 May 17
Utility
Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
15 Mar 22
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV).
Derek Jantz, James Jefferson Smith
Filed: 28 Oct 20
Utility
Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
8 Mar 22
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene.
Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
Filed: 9 Sep 20
Utility
Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
8 Mar 22
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
Filed: 1 Mar 21
Utility
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
30 Nov 21
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton
Filed: 8 Apr 21
Utility
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
12 Oct 21
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome.
James Jefferson Smith, Janel Lape, Victor Bartsevich, Hui Li
Filed: 11 Apr 19
Utility
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
6 Jul 21
The present invention provides a genetically-modified T cell comprising in its genome a modified human T cell receptor alpha gene.
Derek Jantz, James Jefferson Smith, Clayton Beard
Filed: 27 Jun 18
Utility
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
18 May 21
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
Filed: 22 Jun 20
Utility
Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
30 Nov 20
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV).
Derek Jantz, James Jefferson Smith
Filed: 16 Apr 20
Utility
Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
12 Oct 20
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene.
Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
Filed: 4 Oct 16
Utility
Co-stimulatory domains for use in genetically-modified cells
12 Oct 20
The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition.
Derek Jantz, Aaron Martin, Daniel T. MacLeod
Filed: 10 Oct 19
Utility
Treatment of retinitis pigmentosa using engineered meganucleases
31 Aug 20
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 13 Feb 20
Utility
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
17 Aug 20
The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule.
Joann Hux, Aaron Martin, Derek Jantz, Clayton Beard
Filed: 7 Nov 19